Predictive circulating biomarkers of the response to anti‐PD‐1 immunotherapy in advanced HER2 negative breast cancer DOI Creative Commons
Yuhan Wei, Hewei Ge,

Yalong Qi

et al.

Clinical and Translational Medicine, Journal Year: 2025, Volume and Issue: 15(3)

Published: Feb. 25, 2025

Immunotherapy shows promise for treating advanced breast cancer, but only a few patients could respond. Predictive biomarkers from peripheral blood are urgently needed. We designed comprehensive 42-marker mass cytometry panel to profile the samples 57 diagnosed with HER2-negative cancer receiving anti-PD-1 combination therapy. Patients were categorized as responders and non-responders according 6-month progression-free survival (PFS), followed by phenotypic functional comparations identify candidate predictive biomarkers. Longitudinal analysis of paired further revealed dynamic changes in these specific subpopulations. Non-responders exhibited significantly higher frequencies CD39+ Tregs (adjusted p = .031) T-cell milieu at baseline, which positive correlation PD-1+ T cells NR group. assessment indicated significant decrease an increase following treatment, suggesting their potential role immunotherapy resistance. In myeloid compartment, showed CCR2+ monocyte-derived dendritic cell than .037). These positively correlated other negatively naïve non-responders. Based on two efficacy-related biomarkers, we developed prognostic prediction model confirmed its superiority distinguishing patient PFS (p < .001). Peripheral response, serving guide therapeutic choices immunotherapy. associated poor response cancer. Higher correlate better outcomes. A based effectively distinguishes survival. offer non-invasive approach choices.

Language: Английский

Predictive circulating biomarkers of the response to anti‐PD‐1 immunotherapy in advanced HER2 negative breast cancer DOI Creative Commons
Yuhan Wei, Hewei Ge,

Yalong Qi

et al.

Clinical and Translational Medicine, Journal Year: 2025, Volume and Issue: 15(3)

Published: Feb. 25, 2025

Immunotherapy shows promise for treating advanced breast cancer, but only a few patients could respond. Predictive biomarkers from peripheral blood are urgently needed. We designed comprehensive 42-marker mass cytometry panel to profile the samples 57 diagnosed with HER2-negative cancer receiving anti-PD-1 combination therapy. Patients were categorized as responders and non-responders according 6-month progression-free survival (PFS), followed by phenotypic functional comparations identify candidate predictive biomarkers. Longitudinal analysis of paired further revealed dynamic changes in these specific subpopulations. Non-responders exhibited significantly higher frequencies CD39+ Tregs (adjusted p = .031) T-cell milieu at baseline, which positive correlation PD-1+ T cells NR group. assessment indicated significant decrease an increase following treatment, suggesting their potential role immunotherapy resistance. In myeloid compartment, showed CCR2+ monocyte-derived dendritic cell than .037). These positively correlated other negatively naïve non-responders. Based on two efficacy-related biomarkers, we developed prognostic prediction model confirmed its superiority distinguishing patient PFS (p < .001). Peripheral response, serving guide therapeutic choices immunotherapy. associated poor response cancer. Higher correlate better outcomes. A based effectively distinguishes survival. offer non-invasive approach choices.

Language: Английский

Citations

1